Q1 FY27 Total Income up 164% YoY at ₹386.7 cr; PAT up 93% at ₹48.2 cr

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

FCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.6%Reaction day

₹41.85

prior close

₹43.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-6.1% vs market

Specialty Chemicals peers, median of 92sector-0.0%-5.6% vs sector

On the reaction day the stock moved 6.1 pts less than Nifty Microcap 250 and 5.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.5

10m

-5.5

15m

-5.9

30m

-8.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.6+0.4-6.1-0.0-5.6

Next day

-3.2+1.8-5.0+1.4-4.6

-3.0+0.5-3.4+0.5-3.5

-6.5+0.9-7.4+0.9-7.4

-9.6+0.3-9.9-0.7-8.9

-5.9+1.4-7.3+0.2-6.1

-8.3+3.2-11.5+2.0-10.2

15d

+3.7+5.4-1.7+3.1+0.6

+18.3+6.4+11.9+2.2+16.1

+34.5+6.3+28.1+2.6+31.8

+13.8-3.6+17.4-7.0+20.8

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 92Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fineotex Chemical reported Q1 FY27 total income of ₹386.72 crore, up 164% YoY. EBITDA rose 135% to ₹59.14 crore (margin 15.70%); PAT grew 93% to ₹48.21 crore. Growth was supported by CrudeChem acquisition integration in oil and gas specialty chemicals, a capacity expansion at the Texas facility (total capacity now about 1,48,000 MTPA), and improved operational efficiencies. Gross margin improved to 35.42%. ROIC at 33.06%, ROCE at 25.56%.

Likely market impact

Strong all-round growth on back of CrudeChem acquisition; margins and returns healthy. Capacity expansion supports future growth.